LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
JPMorgan Chase & Co. filed an amendment to a Schedule 13G/A reporting beneficial ownership of 1,427,568 shares of LB Pharmaceuticals Inc. Common Stock, representing 4.9% of the class as reported.
The filing shows sole voting power over 1,311,423 shares and sole dispositive power over 1,427,568 shares. The reported filing cites affiliated entities including JPMorgan Chase Bank, N.A. and J.P. Morgan Investment Management Inc. The amendment is signed by a Vice President on 05/13/2026.
LB Pharmaceuticals Inc filed a prospectus supplement to its Form S-1 to update the registration materials with information from its Form 10-Q for the quarterly period ended March 31, 2026.
The supplement incorporates the company’s March quarter results: combined cash, cash equivalents and marketable securities of $365.6 million, a net loss of $(19.054) million for the three months ended March 31, 2026, and 28,676,652 shares of common stock outstanding as of May 7, 2026. The filing discloses a February 2026 private placement that raised approximately $100.0 million (net proceeds ~$93.8 million) and reiterates that current capital resources are expected to fund operations into at least the second quarter of 2029.
LB Pharmaceuticals Inc. reported a larger net loss as it ramped up late-stage development of its lead drug LB-102 while significantly strengthening its balance sheet. For the quarter ended March 31, 2026, net loss widened to $19.1 million, driven by higher research and development expenses of $14.6 million and general and administrative costs of $7.5 million.
Cash, cash equivalents and marketable securities rose to $365.6 million, helped by a $100.0 million February 2026 private placement of common stock and pre-funded warrants. Operating cash burn was $23.3 million in the quarter. The company expects its current capital to fund operations into the second quarter of 2029 as it runs a Phase 3 schizophrenia trial (NOVA-2), a Phase 2 bipolar depression trial (ILLUMINATE-1), an open-label safety study (NOVA-3), and prepares a Phase 2 adjunctive major depressive disorder trial.
LB Pharmaceuticals reported first quarter 2026 results and highlighted progress on its lead drug LB-102 across multiple neuropsychiatric indications. The company ended March 31, 2026 with cash, cash equivalents and marketable securities of $365.6 million, which it expects will fund operations into the second quarter of 2029.
Research and development expenses rose to $14,645 thousand from $3,421 thousand a year earlier, and general and administrative expenses increased to $7,459 thousand from $3,008 thousand, leading to a net loss of $19,054 thousand versus $5,306 thousand. The pivotal Phase 3 NOVA-2 trial in acute schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression have been initiated, with additional Phase 2 work in adjunctive major depressive disorder planned following a $100 million private placement.
LB Pharmaceuticals Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect three Class I directors and ratify the appointment of BDO USA, P.C. as independent auditor for the year ending December 31, 2026.
The company has a classified nine‑member board and states that a majority of directors are independent under Nasdaq rules, with Scott Garland serving as independent chair. Committees oversee audit, compensation, and governance, and the proxy details director qualifications, independence determinations, and risk‑oversight responsibilities.
The filing outlines executive pay, including 2025 total compensation of $11,884,985 for CEO Heather Turner, largely driven by stock options, and explains annual bonus targets of 55% of salary for the CEO and 40% for key officers. It also discloses severance and change‑in‑control protections, and shows BDO audit fees of $616,325 in 2025 and total fees of $658,325.
LB Pharmaceuticals Inc registered for resale up to 4,778,491 shares of Common Stock pursuant to a prospectus dated April 14, 2026, covering (i) 4,723,678 shares related to a February 4, 2026 PIPE (including 3,306,571 outstanding shares and 1,417,107 issuable upon exercise of pre-funded warrants) and (ii) 54,813 shares issued to Maxim upon exercise of prior warrants. The registration permits resale "from time to time" by the Selling Stockholders; the company will not receive proceeds from these resales except for the $0.0001 per-share exercise price of any pre-funded warrants exercised for cash. The prospectus states resale methods may include fixed price, market-price, negotiated transactions, underwriters, broker-dealers or agents. The company reported a Nasdaq last sale price of $25.69 per share as of April 2, 2026.
LB Pharmaceuticals Inc is registering up to 4,778,491 shares of common stock for resale by existing holders. The registration covers 4,723,678 shares held by PIPE investors, including 3,306,571 outstanding shares and 1,417,107 shares issuable upon exercise of pre-funded warrants, plus 54,813 shares issued to Maxim Partners LLC.
The company will not receive proceeds from the resale of these shares, other than the nominal $0.0001 per share exercise price if any pre-funded warrants are exercised for cash. LB Pharmaceuticals is a late-stage biopharmaceutical company focused on LB-102, a lead candidate for schizophrenia, bipolar depression, and adjunctive major depressive disorder.
LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on neuropsychiatric disorders, built around its lead candidate LB-102, a novel, methylated benzamide antipsychotic. LB-102 is designed to improve on amisulpride by enhancing blood–brain barrier penetration, enabling lower, once-daily dosing while preserving a selective D2/D3/5-HT7 receptor profile.
The company reported positive results from a four-week Phase 2 trial in acute schizophrenia, where LB-102 achieved statistically significant reductions in PANSS total scores across 50 mg, 75 mg, and 100 mg doses, with responder rates up to 78.3% and a tolerability profile characterized by low rates of EPS (including akathisia), minimal sedation, and few gastrointestinal effects. Exploratory analyses suggested benefits on negative symptoms and cognition using the CogState battery, with effect sizes increasing by dose and mediation analyses indicating a primarily direct cognitive effect.
LB Pharmaceuticals has initiated a six-week Phase 3 schizophrenia trial (NOVA-2) in the United States comparing 50 mg and 100 mg LB-102 versus placebo, targeting approximately 460 patients, and expects topline data in the second half of 2027. It is also running or planning Phase 2 programs in bipolar 1 depression (ILLUMINATE-1, topline data expected in the first quarter of 2028) and adjunctive major depressive disorder, and is developing a long-acting injectable formulation to address adherence. The company holds global rights to LB-102 and intends to retain U.S. commercialization while evaluating ex-U.S. collaborations.